Track Aurinia Pharmaceuticals Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Aurinia Pharmaceuticals Inc. AUPH · Stock Open Aurinia Pharmaceuticals Inc. in new tab

15.73 USD
P/E
6.90
EPS
2.28
P/B
3.21
ROE
61.42
Beta
1.34
Target Price
18.29 USD
Loading chart...
Key Metrics
Earnings dateFeb. 25, 2027
P/E6.90
EPS2.28
Book Value4.91
Price to Book3.21
Debt/Equity8.92
% Insiders6.807%
Growth
Revenue Growth0.14%
Earnings Growth0.01%
Estimates
Forward P/E13.56
Forward EPS1.16
Target Mean Price18.29

DCF valuation

Model fair value for Aurinia Pharmaceuticals Inc. (AUPH)
Result
Sign in to run the valuation for AUPH.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
7 analysts · consensus Buy · mean target 18.29 USD (low 16.00, high 21.00) · as of 14 Nov 2026
Low 16.00
Mean 18.29
High 21.00
Price 15.73
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Aurinia Pharmaceuticals Inc. Logo Aurinia Pharmaceuticals Inc. Analysis (AUPH)

Canada Health Care Official Website Stock

Is Aurinia Pharmaceuticals Inc. a good investment? Aurinia Pharmaceuticals Inc. (AUPH) is currently trading at 15.73 USD. Market analysts have a consensus price target of 18.29 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 6.90. This relatively low multiple may signal that Aurinia Pharmaceuticals Inc. is undervalued compared to historical market norms.

Earnings Schedule: Aurinia Pharmaceuticals Inc. is expected to release its next earnings report on Feb. 25, 2027. The market consensus estimate for Forward EPS is 1.16.

Investor FAQ

Does Aurinia Pharmaceuticals Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Aurinia Pharmaceuticals Inc.?

Aurinia Pharmaceuticals Inc. is classified as a Stock. You can compare it against 4 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 25, 2027. The company currently has a trailing EPS of 2.28.

Company Profile

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.

Exchange Ticker
FRA (Germany) IKAP.F
STU (Germany) IKAP.SG
LSE (United Kingdom) 0UJF.L
NMS (United States) AUPH
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Oct. 23, 2013 1:50
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion